Here are the biggest calls on Wall Street on Wednesday:
RBC initiates Eli Lilly at outperform
RBC says the weight-loss drugmaker is best positioned to address obesity.
“We favor Lilly (TP $1,250) as our top momentum pick given its GLP-1 franchise strength and the orforglipron oral launch.”
Bank of America downgrades Molson Coors to underperform from neutral
Bank of America says the brewer’s outlook was weaker than expected.
“We lower our price objective to $42 from $50, based on an unchanged ~9x P/E multiple on 2027 EPS estimates. TAP’s FY26 outlook was weaker than expected and, in our view, provided limited visibility into stabilizing volumes.”
MoffettNathanson reiterates Apple as neutral
MoffettNathanson raised its price target on the iPhone maker.
“Thanks to positive earnings revisions in the wake of Apple’s strong December quarter, Apple’s valuation is now more reasonable, in our view. We are raising our target price to $270 (from $241). We maintain our Neutral rating.”
Rothschild & Co Redburn reiterates Nvidia as buy
The firm said in an open letter to CEO Jensen Huang ahead of earnings that Nvidia faces several issues.
“Six potential threats over the next eight quarters. As we head into earnings and then GTC San Jose in March 2026, the market will be responsive to your perspective on six potential strategic threats.”
Goldman Sachs reiterates Advanced Micro Devices as neutral
Goldman raised its price target to $240 per share from $215 following the chipmaker’s deal with Meta Platforms on Tuesday.
“On February 24 before the market open, AMD and Meta announced a strategic partnership to deploy 6GW of AMD GPUs over the next five years.”
Bank of America reiterates Amazon as buy
Bank of America says sentiment will improve once Amazon Web Services revenue accelerates.
“Amazon shares are down 6% since 4Q earnings (vs. the S&P 500 at +1%) as investors have questioned elevated sector investment levels and returns on AI spend. However, we think sentiment can improve as AWS revenues accelerate, Trainium adoption increases, and new AI deals are signed, validating Amazon’s lower-cost strategy.”
Oppenheimer initiates BioAge Labs at outperform
Oppenheimer says the biotech company is at the “dawn of healthy aging.”
“We initiate coverage of BioAge Labs (BIOA) with a $60 PT...”
Oppenheimer upgrades Oracle to outperform from perform
The investment bank sees a more “favorable” risk/reward.
“We upgrade ORCL to Outperform from Perform and initiate a $185 PT. While our call may be early, since it will take time for Oracle to show financial success as a more capital-intensive business in future results, we see a favorable risk/reward after the stock’s multiples have been cut by more than half since September.”
Jefferies upgrades Enphase to buy from hold
Jefferies sees upside for the solar inverter provider.
“We see room for shares to move higher as ENPH executes against stale expectations and continues to innovate its product offering amid an evolving residential solar landscape.”
Morgan Stanley reiterates Netflix as overweight
Morgan Stanley says it is sticking with Netflix despite uncertainty over a potential deal involving Warner Bros. Discovery.
“For OW NFLX, we believe there is opportunity to create value even at a higher bid, but proving out a stand-alone growth plan is also key to a positive re-rating.”
Wells Fargo initiates Live Nation at overweight
Wells Fargo says the concert promoter is firing on all cylinders.
“Digging into Venue Nation, we’re bullish on LYV’s strategy to deploy capex to be a concert owner/operator. We value VN at $133/sh: 65% of our LYV PT of $204/sh. Ticketmaster is facing change, but outcomes are manageable. Initiate at Overweight.”
UBS initiates Ceva at buy
UBS says shares of the software IP company have further upside.
“We initiate coverage of CEVA with a Buy rating and a $27 PT reflecting 34% upside.”
UBS upgrades IBM to neutral from sell
UBS says it sees a more balanced risk/reward.
“We upgrade IBM shares to Neutral from Sell as the risk/reward going forward is more balanced in our view.”
Baird downgrades First Solar to neutral from outperform
Baird downgraded First Solar following earnings.
“Downgrading to Neutral following mixed Q4 results and several question marks in the forward outlook.”
Wells Fargo upgrades Lincoln National to overweight from equal weight
Wells Fargo says “momentum is gathering.”
“We are now resuming estimates for Lincoln buying back stock in 2026 (albeit modestly), with an acceleration in 2027 and 2028. We estimate there’s now enough flexibility to manage the redemption of preferred securities (nearly $1B) in 2027 while maintaining the ability to return capital to shareholders.”
Wells Fargo downgrades Kroger to equal weight from overweight
Wells called Kroger’s risk/reward “unappealing.”
“Turning more cautious; downgrade to EW. While we see opportunity under new leadership, we also expect investment against an already challenged grocery backdrop in ’26. We see near-term earnings risk with muted core growth at best. Risk/reward unappealing.”
JPMorgan upgrades Aura Minerals to overweight from neutral
JPMorgan sees a “golden opportunity” in the gold miner.
“We initiate coverage on Aura Minerals (AUGO US) with an Overweight rating and a YE26 PT of $105/sh (upside of 30%).”
Bank of America double downgrades Fox to underperform from buy
The firm says it is concerned about the NFL renewal.
“We downgrade Fox to Underperform from Buy and lower the PO to $45 (from $80). Our prior bullish view was driven by Fox’s asset mix, which is biased to sports and news. However, we view Fox as the most exposed stock in our coverage to the upcoming NFL renewal.”
Bernstein reiterates Cava Group as outperform
Bernstein raised its price target to $84 per share from $75 following earnings.
“Longer term, Cava has multiple structural levers to maintain its momentum.”
Loop upgrades Trex to buy from hold
Loop upgraded the wood decking company following earnings.
“We are upgrading TREX to Buy from a Hold rating and increasing our PT to $53 (+$8) for several reasons after its 4Q25 beat.”
Comments